Navignostics is a company dedicated to fighting cancer by enabling personalized treatments. Founded in 2022 as a spin-off from the University of Zurich Bodenmiller Lab, Navignostics combines highly multiplex tumor imaging with advanced data analytics. Their technology, validated through rigorous clinical research, analyzes tumor samples to determine the best way to target each cancerous growth. This helps clinicians find the right therapy for each patient and supports researchers in developing new drugs. The company's laboratory and headquarters are located in Horgen, Switzerland.

The company employs spatial single-cell proteomics, using highly multiplex imaging technology to detect and visualize up to 50 proteins from a single tumor tissue section. Their imaging mass cytometry system measures metal-labeled antibodies in the tissue to generate high-resolution digital images of the tumor's molecular composition. Proprietary computational workflows analyze these images to provide detailed information on tumor features, including protein expressions, cell types, cellular interactions, and multicellular assemblies. The results are compiled into clear, comprehensive PDF reports to aid clinicians and researchers.

Navignostics values trust in quality, curiosity to continuously learn and improve cancer care, and fostering supportive relationships to grow together in battling cancer. Their team consists of scientists, lab technicians, software developers, and business experts, including co-founders and various specialists.